Remedium's lead candidate is the only single injection gene therapy based on the clinically proven anabolic mechanism of FGF18, which has demonstrated the ability to reverse cartilage loss in a ...
BOSTON, Sept. 15, 2021 /PRNewswire/ -- Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is proud to announce it has entered into a Sponsored Research Agreement with Tufts ...
AAV2-FGF18 appears to have a wide therapeutic safety window and is able to induce chondrogenesis at very low, locally administered doses The FGF18 gene therapy appears to induce chondrogenesis by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results